Nexus Investment Management Ulc Gilead Sciences, Inc. Transaction History

Nexus Investment Management Ulc

  • $950 Million
  • Q2 2024

A detailed history of Nexus Investment Management Ulc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Nexus Investment Management Ulc holds 288,418 shares of GILD stock, worth $24.1 Million. This represents 2.08% of its overall portfolio holdings.

Number of Shares
288,418
Previous 289,478 0.37%
Holding current value
$24.1 Million
Previous $21.2 Million 6.68%
% of portfolio
2.08%
Previous 2.05%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024
SELL
$63.15 - $72.88 $66,939 - $77,252
-1,060 Reduced 0.37%
288,418 $19.8 Million
Q1 2024

Apr 10, 2024
SELL
$71.58 - $87.29 $35,790 - $43,645
-500 Reduced 0.17%
289,478 $21.2 Million
Q4 2023

Jan 19, 2024
SELL
$73.27 - $83.09 $145,807 - $165,349
-1,990 Reduced 0.68%
289,978 $23.5 Million
Q3 2023

Oct 11, 2023
BUY
$73.94 - $80.67 $33,642 - $36,704
455 Added 0.16%
291,968 $21.9 Million
Q2 2023

Jul 07, 2023
SELL
$76.01 - $86.7 $148,599 - $169,498
-1,955 Reduced 0.67%
291,513 $22.5 Million
Q1 2023

Apr 04, 2023
SELL
$77.31 - $88.08 $57,982 - $66,060
-750 Reduced 0.25%
293,468 $24.3 Million
Q4 2022

Jan 09, 2023
BUY
$62.32 - $89.47 $961,286 - $1.38 Million
15,425 Added 5.53%
294,218 $25.3 Million
Q3 2022

Oct 07, 2022
BUY
$59.54 - $68.01 $171,177 - $195,528
2,875 Added 1.04%
278,793 $17.2 Million
Q2 2022

Jul 06, 2022
SELL
$57.72 - $65.01 $2.17 Million - $2.44 Million
-37,550 Reduced 11.98%
275,918 $17.1 Million
Q1 2022

Apr 08, 2022
BUY
$57.92 - $72.58 $170,864 - $214,111
2,950 Added 0.95%
313,468 $18.6 Million
Q4 2021

Jan 13, 2022
SELL
$64.88 - $73.64 $116,783 - $132,552
-1,800 Reduced 0.58%
310,518 $22.5 Million
Q3 2021

Oct 07, 2021
SELL
$67.69 - $73.03 $208,349 - $224,786
-3,078 Reduced 0.98%
312,318 $21.8 Million
Q2 2021

Jul 13, 2021
BUY
$63.47 - $69.35 $287,201 - $313,808
4,525 Added 1.46%
315,396 $21.7 Million
Q1 2021

Apr 09, 2021
BUY
$60.0 - $68.46 $1.12 Million - $1.28 Million
18,655 Added 6.38%
310,871 $20.1 Million
Q4 2020

Jan 11, 2021
BUY
$56.65 - $64.55 $72,228 - $82,301
1,275 Added 0.44%
292,216 $16.7 Million
Q3 2020

Oct 05, 2020
BUY
$62.1 - $78.08 $122,647 - $154,208
1,975 Added 0.68%
290,941 $18.4 Million
Q2 2020

Jul 08, 2020
SELL
$72.34 - $84.0 $1.32 Million - $1.54 Million
-18,300 Reduced 5.96%
288,966 $22.2 Million
Q1 2020

Apr 03, 2020
BUY
$62.63 - $80.22 $278,703 - $356,979
4,450 Added 1.47%
307,266 $23 Million
Q4 2019

Jan 06, 2020
BUY
$61.62 - $67.78 $1.83 Million - $2.02 Million
29,775 Added 10.9%
302,816 $19.7 Million
Q3 2019

Oct 09, 2019
SELL
$62.51 - $69.0 $203,157 - $224,250
-3,250 Reduced 1.18%
273,041 $17.3 Million
Q2 2019

Jul 12, 2019
BUY
$61.87 - $69.38 $421,953 - $473,171
6,820 Added 2.53%
276,291 $18.7 Million
Q1 2019

Apr 04, 2019
BUY
$62.53 - $70.05 $389,249 - $436,061
6,225 Added 2.36%
269,471 $17.5 Million
Q4 2018

Jan 14, 2019
BUY
$60.54 - $79.0 $110,364 - $144,017
1,823 Added 0.7%
263,246 $16.5 Million
Q3 2018

Oct 10, 2018
BUY
$71.28 - $78.92 $2,280 - $2,525
32 Added 0.01%
261,423 $20.2 Million
Q2 2018

Jul 13, 2018
BUY
$64.88 - $75.68 $133,004 - $155,144
2,050 Added 0.79%
261,391 $18.5 Million
Q1 2018

Apr 05, 2018
BUY
$72.84 - $88.8 $50,988 - $62,160
700 Added 0.27%
259,341 $19.6 Million
Q4 2017

Jan 11, 2018
BUY
$71.15 - $83.52 $16,008 - $18,792
225 Added 0.09%
258,641 $18.5 Million
Q3 2017

Oct 12, 2017
BUY
$72.11 - $85.47 $18.6 Million - $22.1 Million
258,416
258,416 $20.9 Million

Others Institutions Holding GILD

# of Institutions
1,879
Shares Held
1.02B
Call Options Held
12M
Put Options Held
8.96M
View Full List

About GILEAD SCIENCES, INC.

GILD Quotes by TradingView
  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $105B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Nexus Investment Management Ulc Portfolio

Follow Nexus Investment Management Ulc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nexus Investment Management Ulc, based on Form 13F filings with the SEC.

News

Stay updated on Nexus Investment Management Ulc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email